2 registrations that name artichoke Extract as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT07405814
Clinical Trial On The Effect Of Artisterol On Risk Factors In Individuals With Suboptimal Cholesterol Levels
No phase
Zentiva, k.s.
About 106 people
Started Apr 24, 2026
In plain words A study of artichoke Extract in people 18 to 70, run by Zentiva, k.s.. It plans to enroll about 106 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Hyperlipoproteinemia.
Female or male, 18-70 years old.
Subjects with mild hypercholesterolemia previously untreated (LDL-C levels between 115 and 160 mg/dL.
Written informed consent has been obtained during screening visit prior to any study specific procedure.
Subject must understand the informed consent form and other study documents and are willing and able to comply with scheduled visits and requirements of the study protocol, including study specific Dietary Recommendations .
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
investigational product containing phytosterol, artichoke extract and thiamin; Placebo
Registered summary
The goal of this clinical trial is to learn if Artisterol works to lower LDL cholesterol and other metabolic and vascular risk factors in adults. The main questions it aims to answer are: • Does Artisterol lower low-density lipoprotein cholesterol (LDL-C) levels in participants and by how much? Researchers will compare Artisterol to a placebo (a look-alike substance that contains no drug) to see if Artisterol works to lower LDL cholesterol. The full summary is on the listing.
Where, as registered
No US site; Poland (1).
RecruitingNCT06798948
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Phase 2
Li Lab,MD
About 100 people
Started Mar 1, 2025
In plain words A Phase 2 study of artichoke Extract in people 18 to 65, run by Li Lab,MD. It plans to enroll about 100 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Metabolic-associated Fatty Liver Disease (MAFLD).
Subjects who meet the clinical diagnostic criteria for metabolic-associated fatty liver disease and have mild to moderate fatty liver.
Aged 18-65, regardless of gender.
Have not taken any liver-protecting medications in the past 3 months.
Informed subjects who voluntarily sign the informed consent form and agree to participate in all visits and treatments as required by the trial protocol.
The exclusion criteria are on the listing.
What it tests, as registered
Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra; Placebo maltodextrin
Registered summary
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals. With the prevalence of obesity and type 2 diabetes, the morbidity and incidence of MAFLD have been increasing globally, particularly in China. MAFLD and metabolic syndrome as well as type 2 diabetes are mutually causal, jointly promoting the incidence of atherosclerotic cardiovascular disease, chronic kidney disease, liver decompensation, and malignant tumors such as hepatocellular carcinoma. The full summary is on the listing.